Jeri Williams, MD
Neurology · Bakersfield, CANPI 1285825455
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.2%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Amneal Pharmaceuticals LLC at 27.7% of the total. Reporting peaked in 2024 at $11,836 and has fallen 69.2% since, to $3,648 in 2025. Among neurology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 907 payments — averaging $45.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amneal Pharmaceuticals LLC$12K
- Jazz Pharmaceuticals Inc.$8K
- Acadia Pharmaceuticals Inc$4K
- MDD US Operations, LLC$2K
- AbbVie$2K
- Abbott$2K
- plus $12K from 54 others
Across 6 payments — averaging $2750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$17K
What the payments were for
- Consulting fees$8,07519%
- Speaking & faculty fees$10,76426%
- Travel & lodging$2,3716%
- Food & beverage$18,43544%
- Education$8622%
- Gifts$1,1623%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYTARY$10,004
- NUPLAZID$2,850
- SUVECALTAMIDE$1,800
- MYOBLOC$1,162
- INFINITY$893
- CREXONT$716
- Infinity DBS Pulse Generators$469
- GENERAL DBS$283
- BOTOX$239
- AIMOVIG$125
- Austedo XR$125
- GOCOVRI$123
- NOURIANZ$120
- INGREZZA$118
- DYSPORT$113
How this compares
$41,669 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 19 | $787,789 |
| IngrezzaValbenazine Tosylate | 60 | $493,347 |
| NuplazidPimavanserin Tartrate | 55 | $323,727 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $241,226 |
| Nurtec OdtRimegepant Sulfate | 44 | $74,847 |
| GocovriAmantadine Hcl | 19 | $66,436 |
| RytaryCarbidopa/Levodopa | 47 | $54,543 |
| MysolinePrimidone | 11 | $41,419 |
| Aimovig AutoinjectorErenumab-Aooe | 43 | $37,461 |
| Emgality PenGalcanezumab-Gnlm | 28 | $26,055 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 544 | $22,075 |
| QuliptaAtogepant | 21 | $21,624 |
| BotoxOnabotulinumtoxina | 11 | $16,274 |
| Rasagiline Mesylate | 44 | $15,145 |
| NeuproRotigotine | 12 | $12,530 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Nurtec Odt | $673 | $862,63663 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $720 | $493,34760 claims |
| Acadia Pharmaceuticals IncNuplazid | $4,161 | $323,72755 claims |
| CSL BehringPrivigen | $222 | $241,22614 claims |
| MDD US Operations, LLCGocovri | $2,284 | $66,43619 claims |
| Amneal Pharmaceuticals LLCRytary | $11,556 | $54,54347 claims |
| AbbVieQulipta, Botox | $2,179 | $37,89832 claims |
| UCB, Inc.Neupro | $466 | $12,53012 claims |
| Upsher-smith Laboratories LLCTopiramate | $142 | $1,410176 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.
Other neurology in Bakersfield
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.